Atom Therapeutics Co. Ltd.
June 16, 2025
Company Presentation
Inflammation
Atom Therapeutics is a privately held Chinese clinical stage pharmaceutical company engaged in new drug discovery and development of treatments for inflammatory and metabolic diseases. We have raised over $170 million including a Series D for $80 million in 2024.
Our development pipeline includes Lingdolinurad (ABP-671), a novel compound for chronic gout treatment. We have completed a global phase 2b study and we are advancing lingdolinurad to global Phase 3 trials and commercialization.
Our second compound is ABP-745 which is about to start a multicounty
Phase 2 clinical trials for acute gout. Other pipelines are under pre-clinical development includes a new molecule (AT-6616 a new antiarrhythmic drug at IND stage.
Company HQ City:
Hangzhou City
Company HQ State:
Zhejiang Province
Company HQ Country:
China
Year Founded:
2012
Lead Product in Development:
Lingodlinurad (ABP-671) for treatment of Gout and Hyperuricemia, (Phase 3)
ABP-745, for treatment of Acute Gout flare, (Phase 2)
AT6616, a new antiarrhythmic drug (IND)
CEO
William Dongfang Shi, PhD.
Year Founded
2012
Development Phase of Lead Product
Phase III
Number of Unlicensed Products Looking for Licensing
Lingdolinurad (ABP-671), ABP-745 and AT6616
When you expect your next catalyst update?
Lingdolinurad (ABP-671) Global Phase 2b gout study readout,
Initiation of ABP-745 Multicounty Phase 2 study
Filing of IND for AT6616
What is your next catalyst (value inflection) update?
Lingodlinurad Phase 2b gout study readout, May 2025
Website
https://atomthera.us/
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}